Plain-English translation of NCT07718243 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether a new medication called bexmarilimab, when combined with an existing immunotherapy drug called nivolumab, can help people whose cancers have become resistant to previous immune-boosting treatments. The idea is that bexmarilimab may change how immune cells work inside the tumor, making it easier for the medication to help your body recognize and attack cancer cells again.
Many people with advanced lung cancer or melanoma initially respond well to immunotherapy, but over time their tumors learn to resist these treatments. This trial exists to see whether adding this new medication can 'reset' the immune system's ability to fight back against these resistant cancers.
You likely qualify if…
You likely don't qualify if…
In the first phase, researchers will give you increasing doses of the new medication paired with a standard dose of nivolumab to find the safest combination. In the second phase, patients with either lung cancer or melanoma will receive the chosen dose. You'll have regular clinic visits for blood work, scans, and physical exams to monitor how the treatment is working and to watch for side effects. The trial involves ongoing treatment until your disease progresses, you experience serious side effects, or you decide to stop.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
United Kingdom